Prevalence and Treatment patterns of lower extremity peripheral arterial disease among patients at risk in ambulatory health settings

Canadian Journal of Cardiology

Volumn 27, Issue 3, 2011, Pages 389.e11-389.e18

  Makowsky, Mark ^a,b   McMurtry, M Sean ^a   Elton, Trevor ^a   Rosenthal, Meagen ^b   Gunther, Mary ^a   Percy, Mark ^a   Wong, Kevin ^a   Fok, Jennifer ^a   Sebastianski, Meghan ^b   Tsuyuki, Ross ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; WARFARIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; CANADA; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL ASSESSMENT; EDINBURGH CLAUDICATION QUESTIONNAIRE; EXERCISE; FEMALE; HUMAN; HYPERTENSION; LEG; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACY STUDENT; PREVALENCE; QUESTIONNAIRE; REST;

EID: 79960803872     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.12.029     Document Type: Article

References (30)

1. Abramson BL, Huckell V, Anand S, et al. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease: executive summary. Can J Cardiol 2005;21:997-1006.
2. Hirsch A, Haskal Z, Hertzer N, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease [Lower Extremity, Renal, Mesenteric, and Abdominal Aortic]). J Am Coll Cardiol 2006;47:e1-e192.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317-24.
4. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: crosssectional study. Atherosclerosis 2004;172:95-105.
5. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18:185-92.
6. Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol 1996;25:282-90.
7. Dagenais GR, Maurice S, Robitaille NM, Gingras S, Lupien PJ. Intermittent claudication in Quebec men from 1974-1986: the Quebec Cardiovascular Study. Clin Invest Med 1991;14:93-100.
8. Belch JJF, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-92.
9. Lovell M, Harris K, Forbes T, et al. Peripheral arterial disease: lack of awareness in Canada. Can J Cardiol 2009;25:39-45.
10. O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004;109:320-3.
11. Hooi JD, Stoffers HE, Kester AD, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD Study. Peripheral Arterial Occlusive Disease. Scand J Prim Health Care 1998;16:177-82.
12. Hooi JD, Kester ADM, Stoffers HEJH, et al. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 2001;153:666-72.
13. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997;12:209-15.
14. Lange S, Diehm C, Darius H, et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes 2004;112:566-73.
15. Ness J, Aronow WS, Newkirk E, McDanel D. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci 2005; 60:255-7.
16. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004; 171:1189-92.
17. Sukhija R, Yalamanchili K, Aronow WS, Kakar P, Babu S. Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic. Cardiol Rev 2005;13:108-10.
18. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis JHW. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41:816.
19. Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992;45:1101-9.
20. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
21. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a metaanalysis of randomized trials. JAMA 2009;301:1909-19.
22. U.S. Preventive Services Task Force (USPSTF). Screening for peripheral arterial disease: recommendation statement. Available at: http://www.ahrq.gov/clinic/uspstfix.htm. Accessed May 4, 2010.
23. American Academy of Family Physicians. Recommendations for periodic health examinations. Clinical care and research. Available at: http://www.aafp.org/x24973.xml. Accessed May 4, 2010.
24. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27.
25. Grindrod KA, Patel P, Martin JE. What interventions should pharmacists employ to impact health practitioners' prescribing practices? Ann Pharmacother 2006;40:1546-57.
26. Majumdar SR, McAlister FA, Furberg CD. From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol 2004;43:1738-42.
27. Collins TC, Petersen NJ, Suarez-Almazor M, Ashton CM. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med 2003;163:1469-74.
28. Ganguli M, Lytle ME, Reynolds MD, Dodge HH. Random versus volunteer selection for a community-based study. J Gerontol A Biol Sci Med Sci 1998;53:M39-M46.
29. Nicolai SP, Kruidenier LM, Rouwet EV, et al. Ankle brachial index measurement in primary care: are we doing it right? Br J Gen Pract 2009; 59:422-7.
30. Zerumsky K, Steinmetz KL, Handler SM, Rodriguez EG. Pharmacist detection of peripheral arterial disease through the use of a handheld Doppler. Pharmacotherapy 2005;25:797-802.